A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2016
At a glance
- Drugs IDH 305 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 29 Nov 2016 Status changed from recruiting to suspended.
- 17 Nov 2016 Planned End Date changed from 1 Oct 2019 to 1 Apr 2020.
- 17 Nov 2016 Planned primary completion date changed from 1 Oct 2019 to 1 Apr 2020.